NewAmsterdam Pharma's Upcoming Investor Conference Schedule
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a pioneering force in the biopharmaceutical landscape, is gearing up for an exciting lineup of investor conferences in June. Recognized for developing oral non-statin medicines aimed at significantly improving the lives of patients at risk for cardiovascular disease (CVD), NewAmsterdam continues to push forward with their mission even as they prepare for these crucial events. The company's innovative approach looks to meet the needs of individuals with elevated low-density lipoprotein cholesterol (LDL-C) who may not have found success with existing therapies.
Highlights of the Conferences
Company management is set to participate in several prestigious investor conferences, giving key stakeholders the opportunity to gain insights into their latest advancements. Here’s a brief overview of what’s to come:
William Blair 45th Annual Growth Stock Conference
Set to take place in Chicago, NewAmsterdam’s CEO, Michael Davidson, M.D., will present a corporate overview on Tuesday, June 3. Attendees can tune in at 3:20 p.m. CT to hear about the company's strategic vision and recent developments in their CVD-focused therapies.
Jefferies Global Healthcare Conference 2025
Following the William Blair event, NewAmsterdam will be at the Jefferies Global Healthcare Conference in New York on Wednesday, June 4. Chief Financial Officer, Ian Somaiya, is scheduled for an engaging fireside chat at 10:30 a.m. ET, where he will discuss the company's financial outlook and market position.
Goldman Sachs 46th Annual Healthcare Conference
Miami will be the location for the final event in this series, with Michael Davidson returning alongside Matthew Phillipe, Executive Vice President and Head of Investor Relations, for a fireside chat on Monday, June 9 at 2:40 p.m. ET. This discussion is anticipated to cover NewAmsterdam's innovative therapies and their potential impact on patients suffering from high LDL-C levels.
Live Webcasts and Access to Presentations
For those unable to attend in person, live webcasts of these vital presentations will be available through the investor relations section of the NewAmsterdam Pharma website. Post-event, archived replays will also be accessible, ensuring that stakeholders can stay informed about the company’s developments and insights shared during these conferences.
About NewAmsterdam Pharma
NewAmsterdam Pharma (Nasdaq: NAMS) stands at the forefront of biopharmaceutical innovation with a mission to enhance patient care within populations suffering from metabolic diseases. Their core focus is on delivering a safe and convenient LDL-lowering therapy. Their flagship product, obicetrapib, is currently under investigation in multiple phase 3 trials as a potent, oral therapy designed to complement statin treatments for patients with elevated LDL-C who are not responding to existing therapies.
Company Contact Information
For inquiries, the company is accessible as follows:
Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
Email: jleady@spectrumscience.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
Email: austin.murtagh@precisionaq.com
Frequently Asked Questions
What is NewAmsterdam Pharma known for?
NewAmsterdam Pharma specializes in developing innovative oral therapies for cardiovascular disease, particularly focusing on LDL-lowering treatments.
When are the upcoming investor conferences?
The conferences are scheduled for June 3, June 4, and June 9 of the upcoming month.
Who will represent the company at these conferences?
Key representatives include CEO Michael Davidson, M.D. and CFO Ian Somaiya, among other executives.
How can stakeholders access the conference presentations?
Live webcasts will be available via the NewAmsterdam Pharma investor relations website, with replays posted afterward.
What is the significance of obicetrapib?
Obicetrapib is a promising oral therapy under investigation that aims to provide a novel solution for lowering LDL-C in patients at risk for cardiovascular disease.